Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4470301
Max Phase: Preclinical
Molecular Formula: C36H46F3N7O3
Molecular Weight: 681.80
Molecule Type: Unknown
Associated Items:
ID: ALA4470301
Max Phase: Preclinical
Molecular Formula: C36H46F3N7O3
Molecular Weight: 681.80
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1cc(N2CCC[C@H](C(=O)NCc3ccc(OC(F)(F)F)cc3)C2)ccn1
Standard InChI: InChI=1S/C36H46F3N7O3/c1-43-18-20-45(21-19-43)28-12-16-44(17-13-28)29-7-10-32(33(22-29)48-2)42-34-23-30(11-14-40-34)46-15-3-4-27(25-46)35(47)41-24-26-5-8-31(9-6-26)49-36(37,38)39/h5-11,14,22-23,27-28H,3-4,12-13,15-21,24-25H2,1-2H3,(H,40,42)(H,41,47)/t27-/m0/s1
Standard InChI Key: YUFYDDHGCLTQIH-MHZLTWQESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 681.80 | Molecular Weight (Monoisotopic): 681.3614 | AlogP: 5.48 | #Rotatable Bonds: 10 |
Polar Surface Area: 85.44 | Molecular Species: BASE | HBA: 9 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 10 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 10.35 | CX LogP: 5.52 | CX LogD: 2.99 |
Aromatic Rings: 3 | Heavy Atoms: 49 | QED Weighted: 0.29 | Np Likeness Score: -1.44 |
1. Liu S, Jiang Y, Yan R, Li Z, Wan S, Zhang T, Wu X, Hou J, Zhu Z, Tian Y, Zhang J.. (2019) Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors., 179 [PMID:31260890] [10.1016/j.ejmech.2019.06.043] |
Source(1):